Additionally, investigations highlight the activation of RIPK1/RIPK3 as a critical upstream target that facilitates the initiation of tumor immunity, indicating its potential therapeutic potential in cancer treatment strategies [64]. The gene discussed is RIPK1; the disease is cancer.